Bioluminescent imaging analyses indicated that tumors with ATF4 KO (Fig. 4e) or ATF4 binding deficiency in the promoters of SLC2A5 or ALDOB (Fig. 4f) exhibited a significant decrease of tumor size on day 21, but not on day 3, post tumor-cell injection, consistently, mice bearing these tumors also exhibited an obviously prolonged survival time (Fig. 4g, h). Here, SLC2A5 is linked to neoplasm.